Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · Real-Time Price · USD

154.06

-1.86 (-1.19%)

At close: Aug 28, 2026, 4:00 PM EDT

154.94

+0.88 (0.57%)

After-hours: Aug 28, 2026, 7:45 PM EDT

Neurocrine Biosciences Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,374	2,861	2,355	1,887	1,489	1,134
Revenue Growth	34.42%	21.45%	24.81%	26.76%	31.34%	8.38%
Gross Profit	2,176	1,793	1,590	1,282	1,002	791.1
Operating Income	866	636.5	597	394.8	249	207.8
Net Income	705.5	478.6	341.3	249.7	154.5	89.6
Earnings Per Share	6.82	4.67	3.29	2.47	1.56	0.92
EPS Growth	101.21%	41.95%	33.20%	58.33%	69.56%	-77.89%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
INGREZZA	2,718	2,514	2,314	1,836	1,428	1,082
CRENESSITY	570.3	301.2	1.7	-	-	-
ONGENTYS and Other Product	-	19	15.4	24.6	13.1	8.2
Royalties	-	-	18.6	21.2	22.3	22.3
Collaboration and Other	-	-	6.1	5.3	5.5	6.1
Revenue (Total)	3,374	2,861	2,355	1,887	1,489	1,134

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	389.8	1,480	1,076	1,032	989.3	711.3
Total Debt	461.6	471.3	455.1	428.4	262.9	440.4
Net Cash (Debt)	-71.8	1,009	621	603.2	726.4	270.9
Net Cash Growth	-	62.50%	2.95%	-16.96%	168.14%	-30.31%
Net Cash Per Share	-0.69	9.84	5.99	5.97	7.34	2.77

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	898.1	782.7	595.4	389.9	339.4	256.5
Capital Expenditures	-27.7	-34	-38.2	-28.3	-16.5	-23.4
Free Cash Flow	870.4	748.7	557.2	361.6	322.9	233.1
Free Cash Flow Growth	64.63%	34.37%	54.09%	11.98%	38.52%	7.12%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	64.48%	62.67%	67.52%	67.96%	67.29%	69.79%
Operating Margin	25.67%	22.25%	25.35%	20.92%	16.73%	18.33%
Pretax Margin	27.87%	24.66%	20.63%	17.60%	14.37%	8.95%
Profit Margin	20.91%	16.73%	14.49%	13.23%	10.38%	7.90%
FCF Margin	25.80%	26.17%	23.66%	19.16%	21.69%	20.57%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	22.58	29.55	40.49	51.85	74.32	90.18
Forward PE	13.80	15.87	18.15	21.34	22.53	24.55
P/FCF Ratio	17.99	18.89	24.80	35.80	35.56	34.66
PS Ratio	4.64	4.94	5.87	6.86	7.71	7.13